UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2012
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-35006 | 93-0979187 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
11500 S. Eastern Ave., Ste. 240, Henderson, NV | 89052 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (702) 835-6300
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 | Results of Operations and Financial Condition. |
On November 7, 2012, Spectrum Pharmaceuticals, Inc. (the Company) filed a Current Report on Form 8-K, as amended by Amendment No. 1 to Form 8-K, reporting the Companys results of operations for the quarter ended September 30, 2012. In the press release filed under Item 9.01 of the Amendment No. 1, the Company inadvertently referred to a three month rather than nine month period regarding its cash from operations. The Company hereby corrects such statement to read as follows: During the nine-month period ended September 30, 2012, net cash provided by operations was approximately $63.9 million. No other information in the press release is revised by this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 9, 2012
SPECTRUM PHARMACEUTICALS, INC. | ||
By: | /s/ Brett L. Scott | |
Brett L. Scott | ||
Senior Vice President and Acting Chief Financial Officer |